布拉氏酵母菌散剂联合阿奇霉素序贯治疗肺炎支原体肺炎继发腹泻患儿的临床研究

Clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia

摘要:

目的 探讨布拉氏酵母菌散剂联合阿奇霉素序贯治疗肺炎支原体肺炎继发腹泻患儿的效果。方法 选取2015年6月至2017年3月肺炎支原体肺炎继发腹泻患儿88例为研究对象，随机数字表法分为对照组（n=44）和研究组（n=44）。对照组采取常规治疗+阿奇霉素序贯治疗，研究组在对照组基础上口服布拉氏酵母菌散剂，用药至阿奇霉素序贯治疗结束。疗程结束后统计比较两组临床症状改善时间、住院时间，以及临床疗效、治疗前后大便次数、肠道菌群失调情况、不良反应发生率。结果 研究组临床症状改善时间及住院时间较对照组缩短（P < 0.05）；研究组治疗有效率高于对照组（P < 0.05）；治疗第3天及第5天研究组患儿大便次数较对照组明显减少（P < 0.05）；两组肠道菌群失调率比较，研究组较对照组低（P < 0.05）；两组不良反应发生率比较差异无统计学意义（P > 0.05）。结论 采用布拉氏酵母菌散剂联合阿奇霉素序贯治疗肺炎支原体肺炎继发腹泻，可有效改善患儿临床症状，缩短住院时间，减少大便次数，改善肠道菌群失调情况，提高治疗效果，且不会增加不良反应发生风险。

Abstract:

Objective To investigate the clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia.Methods A total of 88 children with diarrhea secondary to Mycoplasma pneumoniae pneumonia between June 2015 and March 2017 were divided into control group and study group using a random number table, with 44 children in each group. The children in the control group were given routine treatment combined with azithromycin sequential therapy, and those in the study group were given oral Saccharomyces boulardii powder in addition to the treatment in the control group until the end of azithromycin sequential therapy. After the treatment ended, the two groups were compared in terms of time to improvement of clinical symptoms, length of hospital stay, clinical outcome, defecation frequency before and after treatment, condition of intestinal dysbacteriosis, and incidence of adverse events.Results Compared with the control group, the study group had significantly shorter time to improvement of clinical symptoms and length of hospital stay (P < 0.05). The study group had a significantly higher response rate than the control group (P < 0.05). On days 3 and 5 of treatment, the study group had a significant reduction in defecation frequency compared with the control group (P < 0.05). The study group had a significantly lower rate of intestinal dysbacteriosis than the control group (P < 0.05). There was no significant difference in the incidence of adverse events between the two groups (P > 0.05).Conclusions In the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia, Saccharomyces boulardii powder combined with azithromycin sequential therapy can improve clinical symptoms, shorten the length of hospital stay, reduce defecation frequency and the incidence of intestinal dysbacteriosis, and improve clinical outcomes, and does not increase the risk of adverse events.